Drug Profile

Research programme: stapled peptide therapeutics - Rein Therapeutics/Roche

Alternative Names: ATSP-7041; MDM2/MDMX dual inhibitor for p53-dependent cancers - Rein Therapeutics/Roche

Latest Information Update: 21 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aileron Therapeutics; Roche
Developer Rein Therapeutics; Roche
Class Peptides
Mechanism of Action Protein modulators; Proto-oncogene protein c-mdm2 inhibitors; Tumour suppressor protein p53 stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported CNS disorders; Haematological malignancies; Inflammation; Metabolic disorders; Solid tumours; Viral infections

Most Recent Events

10 Jan 2025 Aileron Therapeutics is now called Rein Therapeutics
28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (IV)
16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com